Mar 12, 2018
Wilson Therapeutics (publ) is pleased to announce the agenda for its Capital Markets Day to be held in Stockholm on Wednesday 21 March 2018.
Members of the senior management team will be joined by Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan. The program will include in-depth discussion on Wilson Disease and WTX101 (bis-choline tetrathiomolybdate), a first-in-class copper-protein-binding agent with a unique mechanism of action currently in Phase 3 development for Wilson Disease.
- Welcome and Introduction
Jonas Hansson, Chief Executive Officer, Wilson Therapeutics
- Wilson Disease – A Physician’s Perspective
Dr. Frederick K. Askari, MD PhD, Associate Professor and Director of the Wilson Disease program at the University of Michigan
- The first potential new drug for Wilson Disease in decades – WTX101 mechanism and key differentiating features
Dr. Thomas Plitz, Chief Scientific Officer, Wilson Therapeutics
- Clinical experience with WTX101 – detailed overview and discussion of Phase 2 data
Dr. Carl Bjartmar, Chief Medical Officer, Wilson Therapeutics and Dr. Frederick K. Askari
- Phase 3 FOCuS study
Dr. Carl Bjartmar
- Market analysis and commercial planning
Dr. Vincent Metzler, Vice President Commercial Planning & Launch Strategy, Wilson Therapeutics
- Drinks & light refreshments
The event, which will be held in English, will take place at GT30, Grev Turegatan 30, Stockholm. Registration onsite will be from 13:30 CET, presentations will commence at 13:45 CET / 08:45 EST and are expected to conclude at 16:15 CET / 11:15 EST. Drinks and light refreshments will be served after the event.
To register to attend the event please email: email@example.com.
The event will also be webcast live. A replay will be made available shortly after the event. Further details on how to join the webcast can be found at www.wilsontherapeutics.com under Investors & Media/Presentations.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information please contact:
Lauren Williams, Head of Investor Relations, Wilson Therapeutics AB
Phone: +44 7958 669 896
Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
SE-111 43 Stockholm
The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CET on March 12, 2018.